4a10

Phase 1

AAllterum Therapeutics, Inc

4a10 is one of 24 therapeutic programs targeting Lymphoblastic Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lymphoblastic LymphomaRecruiting

Lymphoblastic LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

23 competitors in Lymphoblastic Lymphoma

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

5 2

Cytosar

Teva

Approved

5 3

Oncovin

Eli Lilly

Approved

3 4

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

2 5

Tabloid

Akero Therapeutics

Approved

5 6

Cytoxan

BBaxter Healthcare Corporation

Approved

5 7

Purinethol

SStason

Approved

4 8

Fludara

Ninlaro

Cerubidine

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Lymphoblastic Lymphoma

NCT07586618

Clinical

Trials by Indication[1]

Lymphoblastic Lymphoma1 trial

A First in Human, Phase 1, Open-Label Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 4A10 Monotherapy In Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recruiting·AAllterum Therapeutics, Inc·Phase 1·NCT07586618·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 4a10. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 4a10. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Allterum Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAllterum Therapeutics, Inc

4a10

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lymphoblastic Lymphoma1 trial

References

Drug Info

Quick Facts

Related News